Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBerate-Kids
2025-524214-28-00Phase 3Authorised
- Sponsor
- LIB Therapeutics
- Start
- May 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in heterozygous familial hypercholesterolemia (HeFH) comparing Lerodalcibep with Placebo comparator (2 arms). Primary endpoint: Percent change from baseline in LDL-C at Week 24 versus placebo. Planned start May 2026; status: authorised.
02
Drugs
lerodalcibep
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on 2025-524214-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524214-28-00.